personal genomics:
Category: commercial genetic testing
Forbes' Matthew Herper argues that the long-awaited $1000 genome will never actually materialise, due to the overheads associated with medical interpretation. He's right, for those who plan to obtain their genomes through the traditional medical route. However, those with the motivation to take their genetic information into their own hands will be able to follow an alternative, and more affordable, path - and one that brings its own benefits.
Read on »
Posted by Daniel MacArthur at 10:10 AM • •
Category: personal genomics
Personal genomics company 23andMe has made some fairly major announcements this week: a brand new chip, a new product strategy (including a monthly subscription fee), and yet another discount push. What do these changes mean for existing and new customers?
Read on »
Posted by Daniel MacArthur at 8:45 AM • 8 Comments •
Category: direct-to-consumer genetic testing
Two days ago I reported a rumour that the FDA might have convinced genotyping chip provider Illumina to stop providing its products to direct-to-consumer genetic testing companies - a move that would effectively prevent these companies from being able to...
Read on »
Posted by Daniel MacArthur at 5:30 PM • 1 Comments •
Category: personal genomics
Following up on the rumours I posted about yesterday regarding a potential bid by the FDA to choke of direct-to-consumer genetic testing companies' supply of genotyping chips, I received the following statement by email from 23andMe's PR firm: 23andMe is...
Read on »
Posted by Daniel MacArthur at 6:00 PM • 2 Comments •
Category: personal genomics
A recap of useful and interesting links from the increasingly chaotic world of personal genomics, with an emphasis on the current regulatory turmoil in the US.
Read on »
Posted by Daniel MacArthur at 9:00 AM • 5 Comments •
Category: commercial genetic testing
Investigations launched by the FDA and US Congress have potentially set the stage for a large-scale regulatory crackdown on the embryonic direct-to-consumer genetic testing industry. Such a move would be premature, and would do more harm than good to consumers. The industry needs to change, but a more careful, measured approach based on increasing the transparency of genetic tests is the best way forward.
Read on »
Posted by Daniel MacArthur at 9:30 AM • 9 Comments •
Category: FDA
The news for the embryonic personal genomics industry keeps getting worse: today's Congress hearing was a brutal evisceration, aided by a new report on a sting operation aimed at genetic testing companies. As the regulators close in, what does the future hold for those of us seeking to explore our own genetic information?
Read on »
Posted by Daniel MacArthur at 6:00 PM • 14 Comments •
Category: FDA
An article in the Washington Post by reporter Rob Stein includes several "negative experiences" from personal genomics customers. The fact that so few such experiences could be found tells us something about the general satisfaction of customers with their personal genomic data - and a blogger claims that even these anecdotes have been exaggerated in the article for dramatic effect.
Read on »
Posted by Daniel MacArthur at 7:50 AM • 19 Comments •
Category: genomes unzipped
The first ever post on the new group blog I announced yesterday, Genomes Unzipped, is now live: it's Luke Jostins of Genetic Inference talking about the importance of sequencing for the future of personal genomics. Here's a taste:There is a...
Read on »
Posted by Daniel MacArthur at 10:30 AM • 2 Comments •
Category: genomes unzipped
I've started a new group blog about personal genomics, Genomes Unzipped, with a group of fellow scientists and like-minded bloggers.
Read on »
Posted by Daniel MacArthur at 9:45 AM • •
